Nanoparticles for Pulmonary Delivery

  • Alan B. Watts
  • Robert O. WilliamsIIIEmail author
Part of the Advances in Delivery Science and Technology book series (ADST)


This chapter aims to provide a rational for the use of nanoparticles in pulmonary delivery as well as an overview of strategies and physiological implications of nanoparticle delivery to the lungs. Formulation aspects of nanoparticle systems in the form of liquid dispersions and inhaled dry powders are also reviewed. The chapter also addresses the expanse of lung toxicology research surrounding the inhalation of nanoparticulate pollutants present in the environment. The observations of the adsorption, distribution, metabolism, and excretion (ADME) of these insoluble nanoparticles may lead to a greater understanding of biological interactions of inhaled drug nanoparticles and their ultimate site of action.


Inhalation Lung deposition Nanoparticles Nanotechnology 


  1. 1.
    Arnold MM, Gorman EM, Schieber LJ, Munson EJ, Berkland C (2007) NanoCipro encapsulation in monodisperse large porous PLGA microparticles. J Control Release 121:100–109PubMedCrossRefGoogle Scholar
  2. 2.
    Azarmi S, Roa WH, Löbenberg R (2008) Targeted delivery of nanoparticles for the treatment of lung diseases. Adv Drug Deliv Rev 60:863–875PubMedCrossRefGoogle Scholar
  3. 3.
    Beck-Broichsitter M, Gauss J, Packhaeuser C, Lahnstein K, Schmehl T, Seeger W, Kissel T, Gessler T (2009) Pulmonary drug delivery with aerosolizable nanoparticles in an ex vivo lung model. Int J Pharm 367:169–178PubMedCrossRefGoogle Scholar
  4. 4.
    Behr J, Zimmermann G, Baumgartner R, Leuchte H, Neurohr C, Brand P, Herpich C, Sommerer K, Seitz J, Menges G, Tillmanns S, Keller M (2009) Lung deposition of a liposomal cyclosporine A inhalation solution in patients after lung transplantation. J Aerosol Med Pulm Drug Deliv 22:121–129PubMedCrossRefGoogle Scholar
  5. 5.
    Brzoska M, Langer K, Coester C, Loitsch S, Wagner TOF, Mallinckrodt CV (2004) Incorporation of biodegradable nanoparticles into human airway epithelium cells–in vitro study of the suitability as a vehicle for drug or gene delivery in pulmonary diseases. Biochem Biophys Res Commun 318:562–570PubMedCrossRefGoogle Scholar
  6. 6.
    Byron PR (1986) Prediction of drug residence times in regions of the human respiratory tract following aerosol inhalation. J Pharm Sci 75:433–438PubMedCrossRefGoogle Scholar
  7. 7.
    Chalupa DC, Morrow PE, Oberdoster G, Utell MJ, Frampton MW (2004) Ultrafine particle deposition in subjects with asthma. Environ Health Perspect 112:879–882PubMedCrossRefGoogle Scholar
  8. 8.
    Chattopadhyay P, Shekunov BY, Yim D, Cipolla D, Boyd B, Farr S (2007) Production of solid lipid nanoparticles suspensions using supercritical fluid extraction of emulsions (SFEE) for pulmonary delivery using the AERx system. Adv Drug Deliv Rev 59:444–453PubMedCrossRefGoogle Scholar
  9. 9.
    Chen H-W, Su S-F, Chien C-T, Lin W-H, Yu S-L, Chou C-C, Chen JJW, Yang P-C (2006) Titanium dioxide nanoparticles induce emphysema-like lung injury in mice. FASEB J 20:2393–2395PubMedCrossRefGoogle Scholar
  10. 10.
    Chen J-F, Zhou M-Y, Shao L, Wang Y-Y, Yun J, Chew NYK, Chan H-K (2004) Feasibility of preparing nanodrugs by high-gravity reactive precipitation Int. J Pharm 269:267–274Google Scholar
  11. 11.
    Cook RO, Pannu RK, Kellaway IW (2005) Novel sustained release microspheres for pulmonary drug delivery. J Control Release 104:79–90PubMedCrossRefGoogle Scholar
  12. 12.
    Dailey LA, Jekel N, Fink L, Gessler T, Schmehl T, Wittmar M, Kissel T, Seeger W (2006) Investigation of the proinflammatory potential of biodegradable nanoparticle drug delivery systems in the lung. Toxicol Appl Pharmacol 215:100–108PubMedCrossRefGoogle Scholar
  13. 13.
    Dailey LA, Kleemann E, Wittmar M, Gessler T, Schmehl T, Roberts C, Seeger W, Kissel T (2003) Surfactant-free, biodegradable nanoparticles for aerosol therapy based on the branched polyesters. DEAPA-PVAL-g-PLGA. Pharm Res 20:2011–2020PubMedCrossRefGoogle Scholar
  14. 14.
    Dailey LA, Schmehl T, Gessler T, Wittmar M, Grimminger F, Seeger W, Kissel T (2003) Nebulization of biodegradable nanoparticles: impact of nebulizer technology and nanoparticle characteristics on aerosol features. J Control Release 86:131–144PubMedCrossRefGoogle Scholar
  15. 15.
    De Jong WH, Borm PJA (2008) Drug delivery and nanoparticles: applications and hazards. Int J Nanomed 3:133–149CrossRefGoogle Scholar
  16. 16.
    Dellamary LA, Tarara TE, Smith DJ, Woelk CH, Adractas A, Costello ML, Gill H, Weers JG (2000) Hollow porous particles in metered dose inhalers. Pharm Res 17:168–174PubMedCrossRefGoogle Scholar
  17. 17.
    Drew RH, Dodds Ashley E, Benjamin DKJ, Davis RD, Palmer SM, Perfect JR (2004) Comparative safety of amphotericin B lipid complex and amphotericin B deoxycholate as aerosolized antifungal prophylaxis in lung-transplant recipients. Transplantation 77:232–237PubMedCrossRefGoogle Scholar
  18. 18.
    Duddu SP, Sisk SA, Walter YH, Tarra TE, Trimble KR, Clark AR, Eldon MA, Elton RC, Pickford M, Hirst PH, Newman SP, Weers JG (2002) Improved lung delivery from a passive dry powder inhaler using an engineered pulmosphere powder. Pharm Res 19:689–695PubMedCrossRefGoogle Scholar
  19. 19.
    Duffin R, Mills NL, Donaldson K (2007) Nanoparticles – a thoracic toxicology perspective. Yonsei Med J 48:561–572PubMedCrossRefGoogle Scholar
  20. 20.
    Edwards DA, Hanes J, Caponetti G, Hrkach J, Ben-Jebria A, Eskew ML, Mintzes J, Deaver D, Lotan N, Langer R (1997) Large porous particles for pulmonary drug delivery. Science 276:1868PubMedCrossRefGoogle Scholar
  21. 21.
    El-Gendy N, Berkland C (2009) Combination chemotherapeutic dry powder aerosols via controlled nanoparticle agglomeration. Pharm Res 26:1752–1763PubMedCrossRefGoogle Scholar
  22. 22.
    Elder A, Gelein R, Silva V, Feikert T, Opanashuk L, Carter J, Potter R, Maynard A, Ito Y, Finkelstein J (2006) Translocation of inhaled ultrafine manganese oxide particles to the central nervous system. Environ Health Perspect 114:1172–1178PubMedCrossRefGoogle Scholar
  23. 23.
    Ely L, Roa W, Finlay WH, Löbenberg R (2007) Effervescent dry powder for respiratory drug delivery. Eur J Pharm Biopharm 65:346–353PubMedCrossRefGoogle Scholar
  24. 24.
    Engstrom J, Tam J, Miller M, Williams R, Johnston K (2009) Templated open flocs of nanorods for enhanced pulmonary delivery with pressurized metered dose inhalers. Pharm Res 26:101–117PubMedCrossRefGoogle Scholar
  25. 25.
    FDA (2007) Nanotechnology: a report on the U.S. Food and Drug Administration Nanotechnology Task Force, 25 July 2007. RockvilleGoogle Scholar
  26. 26.
    Forte R, Dibble C (1999) The role of international environmental agreements in metered dose inhaler technology changes: pMDI in transition: CFC to HFA formulations. J Allergy Clin Immunol 104:S216–S270CrossRefGoogle Scholar
  27. 27.
    Gao L, Zhang D, Chen M (2008) Drug nanocrystals for the formulation of poorly soluble drugs and its application as a potential drug delivery system. J Nanopart Res 10:845–862CrossRefGoogle Scholar
  28. 28.
    Garcia-Fuentes M, Prego C, Torres D, Alonso MJ (2005) A comparative study of the potential of solid triglyceride nanostructures coated with chitosan or poly(ethylene glycol) as carriers for oral calcitonin delivery. Eur J Pharm Sci 25:133–143PubMedCrossRefGoogle Scholar
  29. 29.
    Grenha A, Seigo B, Remunan-Lopez C (2005) Microencapsulated chitosan nanoparticles for lung protein delivery. Eur J Pharm Biopharm 25:417–437Google Scholar
  30. 30.
    Gumbleton M (2001) Caveolae as potential macromolecule trafficking compartments within alveolar epithelium. Adv Drug Deliv Rev 49:281–300PubMedCrossRefGoogle Scholar
  31. 31.
    Hadinoto K, Phanapavudhikul P, Kewu Z, Tan RBH (2006) Novel formulation of large hollow nanoparticles aggregates as potential carriers in inhaled delivery of nanoparticulate drugs. Ind Eng Chem Res 145:3697–3706CrossRefGoogle Scholar
  32. 32.
    Hadinoto K, Phanapavudhikul P, Kewu Z, Tan RBH (2007) Dry powder aerosol delivery of large hollow nanoparticulate aggregates as prospective carriers of nanoparticulate drugs: effects of phospholipids. Int J Pharm 333:187–198PubMedCrossRefGoogle Scholar
  33. 33.
    Hernández-Trejo N, Kayser O, Steckel H, Müller RH (2005) Characterization of nebulized buparvaquone nanosuspensions – effect of nebulization technology. J Drug Target 13:499–507PubMedCrossRefGoogle Scholar
  34. 34.
    Heurtault B, Saulnier P, Pech B, Proust J-E, Benoit J-P (2002) A novel phase inversion-based process for the preparation of lipid nanocarriers. Pharm Res 19:875–880PubMedCrossRefGoogle Scholar
  35. 35.
    Hirst PH, Pitcairn GR, Weers JG, Tarara TE, Clark AR, Dellamary LA, Hall G, Shorr J, Newman SP (2002) In vivo lung deposition of hollow porous particles from a pressurized metered dose inhaler. Pharm Res 19:258–264PubMedCrossRefGoogle Scholar
  36. 36.
    Hu FQ, Yuan H, Zhang HH, Fang M (2002) Preparation of solid lipid nanoparticles with clobetasol propionate by a novel solvent diffusion method in aqueous system and physicochemical characterization. Int J Pharm 239:121–128PubMedCrossRefGoogle Scholar
  37. 37.
    Hu T, Chiou H, Chan H-K, Chen J-F, Yun J (2008) Preparation of inhalable salbutamol sulphate using reactive high gravity controlled precipitation. J Pharm Sci 97:944–949PubMedCrossRefGoogle Scholar
  38. 38.
    Hureaux J, Lagarce F, Gagnadoux F, Vecellio L, Clavreul A, Roger E, Kempf M, Racineux J-L, Diot P, Benoit J-P, Urban T (2009) Lipid nanocapsules: ready-to-use nanovectors for the aerosol delivery of paclitaxel. Eur J Pharm Biopharm 73:239–246PubMedCrossRefGoogle Scholar
  39. 39.
    Iacono AT, Johnson BA, Grgurich WF, Youssef JG, Corcoran TE, Seiler DA, Dauber JH, Smaldone GC, Zeevi A, Yousem SA, Fung JJ, Burckart GJ, McCurry KR, Griffith BP (2006) A randomized trial of inhaled cyclosporine in lung-transplant recipients. N Engl J Med 354:141–150PubMedCrossRefGoogle Scholar
  40. 40.
    ISO/TS-27687 (2008) ISO Standards, 2008. Nanotechnologies – terminology and definitions for nanoobjects – nanoparticle, nanofibre, and nanoplate, International Organization of StandardizationGoogle Scholar
  41. 41.
    Jacobs C, Müller RH (2002) Production and characterization of a budesonide nanosuspension for pulmonary administration. Pharm Res 19:189–194PubMedCrossRefGoogle Scholar
  42. 42.
    Janakan N, Senevirantne R (2008) Factors contributing to medication noncompliance of newly diagnosed smear-positive pulmonary turberculosis patients in the district of Colombo, Sri Lanka. Asia Pac J Public Health 20:214–223PubMedGoogle Scholar
  43. 43.
    Jaques PA, Kim CS (2000) Measurement of total lung deposition of inhaled ultrafine particles in healthy men and women Inhal Tox 12:715–731PubMedCrossRefGoogle Scholar
  44. 44.
    Jensen DMK, Cun D, Maltesen MJ, Frokjaer S, Nielsen HM, Foged C (2010) Spray drying of siRNA-containing PLGA nanoparticles intended for inhalation. J Control Release 142(1):138–145PubMedCrossRefGoogle Scholar
  45. 45.
    Kane AB, Hurt RH (2008) Nanotoxicology: the asbestos analogy revisited. Nat Nanotechnol 3:378–379PubMedCrossRefGoogle Scholar
  46. 46.
    Kaur IP, Bhandari R, Bhandari S, Kakkar V (2008) Potential of solid lipid nanoparticles in brain targeting. J Control Release 127:97–109PubMedCrossRefGoogle Scholar
  47. 47.
    Keck CM (2010) Particle size analysis of nanocrystals: improved analysis method. Int J Pharm 390(1):3–12PubMedCrossRefGoogle Scholar
  48. 48.
    Kirby AC, Coles MC, Kaye PM (2009) Alveolar macrophages transport pathogens to lung draining lymph nodes. J Immunol 183:1983–1989PubMedCrossRefGoogle Scholar
  49. 49.
    Kisin ER, Murray AR, Keane MJ, Shi X-C, Schwegler-Berry D, Gorelik O, Arepalli S, Castranova V, Wallace WE, Kagan VE, Shvedova AA (2007) Single-walled carbon nanotubes: geno- and cytotoxic effects in lung fibroblast V79 Cells. J Toxicol Environ Health A 70:2071–2079PubMedCrossRefGoogle Scholar
  50. 50.
    Kraft WK, Steiger B, Beussink D, Quiring JN, Fitzgerald N, Greenberg HE, Waldman SA (2004) The pharmacokinetics of nebulized nanocrystal budesonide suspension in healthy volunteers. J Clin Pharmacol 44:67–72PubMedCrossRefGoogle Scholar
  51. 51.
    Kreuter J (2001) Nanoparticulate systems for brain delivery of drugs. Adv Drug Deliv Rev 47:65–81PubMedCrossRefGoogle Scholar
  52. 52.
    Kwon J-T, Hwang S-K, Jin H, Kim D-S, Minai-Tehrani A, Yoon H-J, Choi M, Yoon T-J, Han D-Y, Kang Y-W, Yoon B-I, Lee J-K, Cho M-H (2008) Body distribution of inhaled fluorescent magnetic nanoparticles in the mice. J Occup Health 50:1–6PubMedCrossRefGoogle Scholar
  53. 53.
    Leone-Bay A, Grant M (2006) Technosphere technology: a platform for inhaled protein therapeutics. ONdrugDELIVERY, 8–11Google Scholar
  54. 54.
    Luangvala MM, Castillo MC, Bosco AP (2009) A novel submicron formulation of nebulized budesonide significantly decreases the nebulization time from a variety of commercially available jet nebulizers. J Allergy Clin Immunol 123:S81CrossRefGoogle Scholar
  55. 55.
    Matteucci ME, Hotze MA, Johnston KP, Williams RO III (2006) Drug nanoparticles by antisolvent precipitation: mixing energy versus surfactant stabilization. Langmuir 22:8951–8959PubMedCrossRefGoogle Scholar
  56. 56.
    Matteucci ME, Paguio JC, Miller MA, Williams RO, Johnston KP (2008) Flocculated amorphous nanoparticles for highly supersaturated solutions. Pharm Res 25:2477–2487PubMedCrossRefGoogle Scholar
  57. 57.
    McConville J, Overhoff K, Sinswat P, Vaughn J, Frei B, Burgess D, Talbert R, Peters J, Johnston K, Williams R (2006) Targeted high lung concentrations of itraconazole using nebulized dispersions in a murine model. Pharm Res 23:901–911PubMedCrossRefGoogle Scholar
  58. 58.
    Medina C, Santos-Martinez MJ, Radomski A, Corrigan OI, Radomski MW (2007) Nanoparticles: pharmacological and toxicological significance. Br J Pharmacol 150:552–558PubMedCrossRefGoogle Scholar
  59. 59.
    Mizoe T, Ozeki T, Okada H (2007) Preparation of drug nanoparticle-containing microparticles using a 4-fluid nozzle spray drier for oral, pulmonary, and injection dosage forms. J Control Release 122:10–15PubMedCrossRefGoogle Scholar
  60. 60.
    Mossman BT, Brom PJ, Castranova V, Costa DL, Donaldson K, Kleeberger SR (2007) Mechanisms of action of inhaled fibers, particles and nanoparticles in lung and cardiovascular diseases. Part Fibre Toxicol 4:1–10CrossRefGoogle Scholar
  61. 61.
    Müller RH, Jacobs C, Kayser O (2001) Nanosuspensions as particulate drug formulations in therapy: rationale for development and what we can expect for the future. Adv Drug Deliv Rev 47:3–19PubMedCrossRefGoogle Scholar
  62. 62.
    Newhouse MT, Hirst PH, Duddu SP, Walter YH, Tarara TE, Clark AR, Weers JG (2003) Inhalation of a dry powder tobramycin pulmosphere formulation in healthy volunteers. Chest 124:360–366PubMedCrossRefGoogle Scholar
  63. 63.
    Nguyen J, Steele TWJ, Merkel O, Reul R, Kissel T (2008) Fast degrading polyesters as siRNA nano-carriers for pulmonary gene therapy. J Control Release 132:243–251PubMedCrossRefGoogle Scholar
  64. 64.
    Oberdörster G (2000) Pulmonary effects of inhaled ultrafine particles. Int Arch Occup Environ Health 74:1–8CrossRefGoogle Scholar
  65. 65.
    Onuma K, Sato Y, Ogawara S, Shirasawa N, Kobayashi M, Yoshitake J, Yoshimura T, Iigo M, Fujii J, Okada F (2009) Nano-scaled particles of titanium dioxide convert benign mouse fibrosarcoma cells into aggressive tumor cells. Am J Pathol 175:2171–2183PubMedCrossRefGoogle Scholar
  66. 66.
    Ostrander KD, Bosch HW, Bondanza DM (1999) An in-vitro assessment of a nanocrystal(TM) beclomethasone dipropionate colloidal dispersion via ultrasonic nebulization. Eur J Pharm Biopharm 48:207–215PubMedCrossRefGoogle Scholar
  67. 67.
    Packhaeuser C, Lahnstein K, Sitterberg J, Schmehl T, Gessler T, Bakowsky U, Seeger W, Kissel T (2009) Stabilization of aerosolizable nano-carriers by freeze-drying. Pharm Res 26:129–138PubMedCrossRefGoogle Scholar
  68. 68.
    Pandey R, Khuller GK (2005) Solid lipid particle-based inhalable sustained drug delivery system against experimental tuberculosis. Tuberculosis 85:227–234PubMedCrossRefGoogle Scholar
  69. 69.
    Patton JS, Fishburn CS, Weers JG (2004) The lungs as a portal of entry for systemic drug delivery. Proc Am Thorac Soc 1:338–344PubMedCrossRefGoogle Scholar
  70. 70.
    Peters A, Wichmann H, Tuch T, Heinrich J, Heyder J (1997) Respiratory effects are associated with the number of ultrafine particles. Am J Respir Crit Care Med 155:1376–1383PubMedGoogle Scholar
  71. 71.
    Plumley C, Gorman EM, El-Gendy N, Bybee CR, Munson EJ, Berkland C (2009) Nifedipine nanoparticle agglomeration as a dry powder aerosol formulation strategy. Int J Pharm 369:136–143PubMedCrossRefGoogle Scholar
  72. 72.
    Poland CA, Duffin R, Kinloch I, Maynard A, Wallace WAH, Seaton A, Stone V, Brown S, MacNee W, Donaldson K (2008) Carbon nanotubes introduced into the abdominal cavity of mice show asbestos-like pathogenicity in a pilot study. Nat Nanotechnol 3:423–428PubMedCrossRefGoogle Scholar
  73. 73.
    Powell MC, Kanarack MS (2006) Nanomaterial health effects-part 1: background and current knowledge. Wis Med J 105:16–21Google Scholar
  74. 74.
    Putney SD, Burke PA (1998) Improving protein therapeutics with sustained-release formulations. Nat Biotechnol 16:153–157PubMedCrossRefGoogle Scholar
  75. 75.
    Rabinow BE (2004) Nanosuspensions in drug delivery. Nat Rev Drug Discov 3:785–796PubMedCrossRefGoogle Scholar
  76. 76.
    Rave K, Heise T, Pfutzner A, Boss AH (2007) Coverage of postprandial blood glucose excursions with inhaled technosphere insulin in comparison to subcutaneously injected regular human insulin in subjects with type 2 diabetes. Diabetes Care 30:2307–2308PubMedCrossRefGoogle Scholar
  77. 77.
    Rijnders BJ, Cornelissen JJ, Slobbe L, Becker MJ, Doorduijn JK, Hop WCJ, Ruijgrok EJ, Löwenberg B, Vulto A, Lugtenburg PJ, de Marie S (2008) Aerosolized liposomal amphotericin b for the prevention of invasive pulmonary Aspergillosis during prolonged neutropenia: a randomized, placebo controlled trial. Clin Infect Dis 46:1401–1408PubMedCrossRefGoogle Scholar
  78. 78.
    Seaton A, Godden D, MacnNee W, Donaldson K (1995) Particulate air pollution and acute health effects. Lancet 345:176–178PubMedCrossRefGoogle Scholar
  79. 79.
    Seaton A, Tran L, Aitken R, Donaldson K (2010) Nanoparticles, human health hazard and regulation. J Roy Soc Interface 7:S119–S129CrossRefGoogle Scholar
  80. 80.
    Sham JOH, Zhang Y, Finlay WH, Roa WH, Löbenberg R (2004) Formulation and characterization of spray-dried powders containing nanoparticles for aerosol delivery to the lung. Int J Pharm 269:457–467PubMedCrossRefGoogle Scholar
  81. 81.
    Shi L, Plumley C, Berkland C (2007) Biodegradable nanoparticle flocculates for dry powder aerosol formulation. Langmuir 23:10897–10901PubMedCrossRefGoogle Scholar
  82. 82.
    Shi W, Liu T, Xie L, Wang S (2005) FK506 in a biodegradable glycolide-co-clatide-co-caprolactone polymer for prolongation of corneal allograft survival. Curr Eye Res 30:969–976PubMedCrossRefGoogle Scholar
  83. 83.
    Sinswat P, Overhoff KA, McConville JT, Johnston KP, Williams RO III (2008) Nebulization of nanoparticulate amorphous or crystalline tacrolimus – single-dose pharmacokinetics study in mice. Eur J Pharm Biopharm 69:1057–1066PubMedCrossRefGoogle Scholar
  84. 84.
    Song Y, Li X, Du X (2009) Exposure to nanoparticles is related to pleural effusion, pulmonary fibrosis and granuloma. Eur Respir J 34:559–567PubMedCrossRefGoogle Scholar
  85. 85.
    Stass H, Baumann-Noss S, Delesen H, Nagelschmitz J, Willmann S, Edginton A, Staab D (2008) Pharmacokinetics of ciprofloxacin PulmoSphere® inhalational powder. J Cyst Fibros 7:S26CrossRefGoogle Scholar
  86. 86.
    Suwa T, Hogg JC, Quinlan KB, Ohgami A, Vincent R, Eeden SFV (2002) Particulate air pollution induces progression of atherosclerosis. J Am Coll Cardiol 39:935–942PubMedCrossRefGoogle Scholar
  87. 87.
    Takagi A, Hirose A, Nishimura T, Fukumori N, Ogata A, Ohashi N, Kitajima S, Kanno J (2008) Induction of mesothelioma in p53+/− mouse by intraperitoneal application of multi-wall carbon nanotube. J Toxicol Sci 33:105–116PubMedCrossRefGoogle Scholar
  88. 88.
    Tam JM, McConville JT, Robert O, Williams I, Johnston KP (2008) Amorphous cyclosporin nanodispersions for enhanced pulmonary deposition and dissolution. J Pharm Sci 97:4915–4933PubMedCrossRefGoogle Scholar
  89. 89.
    Tsapis N, Bennett D, Jackson B, Weitz DA, Edwards DA (2002) Trojan particles: Large porous carriers of nanoparticles for drug delivery. Proc Natl Acad Sci USA 99:12001–12005PubMedCrossRefGoogle Scholar
  90. 90.
    Tseng C-L, Su W-Y, Yen K-C, Yang K-C, Lin F-H (2009) The use of biotinylated-EGF-modified gelatin nanoparticle carrier to enhance cisplatin accumulation in cancerous lungs via inhalation. Biomaterials 30:3476–3485PubMedCrossRefGoogle Scholar
  91. 91.
    Tseng C, Wu SY, Wang W, Peng C, Lin F, Lin C, Young T, Shieh M (2008) Targeting efficiency and biodistribution of biotinylated-EGF-conjugated gelatin nanoparticles administered via aerosol delivery in nude mice with lung cancer. Biomaterials 29:3014–3022PubMedCrossRefGoogle Scholar
  92. 92.
    U.K.DERFA (2006) UK voluntary reporting scheme for engineered nanoscale materials. Chemicals and Nanotechnologies Division, DefraGoogle Scholar
  93. 93.
    U.S. FDA (2007) Nanotechnology: a report of the U.S. Food and Drug Administration Nanotechnology Task Force. 25 July 2007
  94. 94.
    Uboldi C, Bonacchi D, Lorenzi G, Hermanns MI, Pohl C, Baldi G, Unger RE, Kirkpatrick CJ (2009) Gold nanoparticles induce cytotoxicity in alveolar type-II cell lines A549 and NCIH44I. Part Fibre Toxicol 6:1–12CrossRefGoogle Scholar
  95. 95.
    Vanbever R, Mintzes JD, Wang J, Nice J, Chen D, Batycky R, Langer R, Edwards DA (1999) Formulation and physical characterization of large porous particles for inhalation. Pharm Res 16:1735–1742PubMedCrossRefGoogle Scholar
  96. 96.
    Vaughn JM, McConville JT, Burgess D, Peters JI, Johnston KP, Talbert RL, Williams RO III (2006) Single dose and multiple dose studies of itraconazole nanoparticles. Eur J Pharm Biopharm 63:95–102PubMedCrossRefGoogle Scholar
  97. 97.
    Venkateswarlu V, Manjunath K (2004) Preparation, characterization and in vitro release kinetics of clozapine solid lipid nanoparticles. J Control Release 95:627–638PubMedCrossRefGoogle Scholar
  98. 98.
    Wang Z, Chen J-F, Le Y, Shen Z-G, Yun J (2007) Preparation of ultrafine beclomethasone dipropionate drug powder by antisolvent precipitation. Ind Eng Chem Res 46:4839–4845CrossRefGoogle Scholar
  99. 99.
    Warheit DB, Laurence BR, Reed KL, Roach DH, Reynolds AM, Webb TR (2004) Comparative pulmonary toxicity assessment of single-wall carbon nanotubes in rats. Toxicol Sci 77:117–125PubMedCrossRefGoogle Scholar
  100. 100.
    Watts AB, Cline AM, Saad AR, Johnson SB, Peters JI, Williams RO (2010) Characterization and pharmacokinetic analysis of tacrolimus dispersion for nebulization in a transplanted rodent model. Int J Pharm 384:46–52PubMedCrossRefGoogle Scholar
  101. 101.
    Watts AB, Son Y-J, McConville JT, Williams RO (2009) Nanostructured tacrolimus produced by ultra-rapid freezing for dry powder inhalation. AAPS Annual Meeting, Los AngelesGoogle Scholar
  102. 102.
    Watts AB, Williams RO (2010) Formulation and production strategies for enhancing ­bioavailability of poorly absorbed drugs. In: Rogge MC, Taft DR (eds) Drugs and the ­pharmaceutical sciences: preclinical drug development. Informa Healthcare, New York, pp 161–195Google Scholar
  103. 103.
    Weiwei Z, Takahisa M, You Han B, Ramesh R, Alfred KC, Steven EK (2006) Development of a sustained-release system for perivascular delivery of dipyridamole. J Biomed Mater Res B Appl Biomater 77B:135–143CrossRefGoogle Scholar
  104. 104.
    Wiedmann TS, DeCastro L, Wood RW (1997) Nebulization of nanocrystals: production of a respirable solid-in-liquid-in-air colloidal dispersion. Pharm Res 14:112–116PubMedCrossRefGoogle Scholar
  105. 105.
    Yamamoto H, Hoshina W, Kurashima H, Takeuchi H, Kawashima Y, Yokoyama T, Tsujimoto H (2007) Engineering of poly(DL-lactic-co-glycolic acid) nanocomposite particles for dry powder inhalation dosage forms of insulin with spray-fluidized bed granulating system. Adv Powder Technol 18:215–228CrossRefGoogle Scholar
  106. 106.
    Yamamoto H, Kuno Y, Sugimoto S, Takeuchi H, Kawashima Y (2005) Surface-modified PLGA nanosphere with chitosan improved pulmonary delivery of calcitonin by mucoadhesion and opening of the intercellular tight junctions. J Control Release 102:373–381PubMedCrossRefGoogle Scholar
  107. 107.
    Yang H-M, Ma JYC, Castranova V, Ma JKH (1997) Effects of diesel exhaust particles on the release of interleukin-1 and tumor necrosis factor-alpha from rat alveolar macrophages. Exp Lung Res 23:269–284PubMedCrossRefGoogle Scholar
  108. 108.
    Yang JZ, Young AL, Chiang P, Thurston A, Pretzer DK (2008) Fluticasone and budesonide nanosuspensions for pulmonary delivery: preparation, characterization, and pharmacokinetic studies. J Pharm Sci 97(11):4869–4878PubMedCrossRefGoogle Scholar
  109. 109.
    Yang W, Peters JI, Williams RO III (2008) Inhaled nanoparticles – a current review. Int J Pharm 356:239–247PubMedCrossRefGoogle Scholar
  110. 110.
    Yang W, Tam J, Miller DA, Zhou J, McConville JT, Johnston KP, Williams RO III (2008) High bioavailability from nebulized itraconazole nanoparticle dispersions with biocompatible stabilizers. Int J Pharm 361:177–188PubMedCrossRefGoogle Scholar
  111. 111.
    Zahoor A, Sadhna S, Khuller GK (2005) Inhalable alginate nanoparticles as antitubercular drug carriers against experimental tuberculosis. Int J Antimicrob Agents 26:298–303PubMedCrossRefGoogle Scholar
  112. 112.
    Zolnik BS, Sadrieh N (2009) Regulatory perspective on the importance of ADME assessment of nanoscale material containing drugs. Adv Drug Deliv Rev 61:422–427PubMedCrossRefGoogle Scholar

Copyright information

© Controlled Release Society 2011

Authors and Affiliations

  1. 1.Division of Pharmaceutics, College of PharmacyUniversity of Texas at AustinAustinUSA

Personalised recommendations